Georgia May Jagger looks up to her supermodel mom Jerry Hall as a beauty inspiration.

By Aziz El Yaakoubi JEDDAH, Saudi Arabia Syrian President Bashar al-Assad is in Saudi Arabia on Friday to

The Philadelphia Phillies are set to play their first Game 7 in franchise history

Manchester City have completed the signing of Josko Gvardiol, making the Croatia international the second most expensive centre-back ever. City have paid RB Leipzig £77 million for the 21-year-old, who passed a medical at the Etihad Stadium on Friday, and he has signed a five-year contract. The fee is just short of the world record for a defender, the £80 million Manchester United paid for Harry Maguire in 2019, and Gvardiol becomes City’s second summer signing, after his international teammate Mateo Kovacic. Gvardiol believes he can improve under Pep Guardiola, who he called the world’s outstanding manager, after agreeing to join the treble winners. He said: “I have always dreamed of one day playing in England and to be doing so now with Manchester City – after the season they have just had – is a real honour for me. “Anyone who saw Manchester City play last season knows they are the best team in the world. To win the treble says everything you need to know about the quality this team has. “To be joining City is something very special for me and my family. To have the chance to work with Pep Guardiola, too, will be amazing for me. I know I am not yet the finished article and I am sure my game will progress under the best coach in football. To be linking up with Mateo Kovacic will also be special. City director of football Txiki Begiristain added: “We are delighted. He is a player we have watched closely, and we feel he has a superb set of attributes. Top clubs all over Europe have been monitoring him, so to bring him here is great news for us. “Josko has so many qualities – everything you want in a centre-half. He is fast, competitive, combative, strong in the air, impressive in possession of the ball, with strong self-belief and a good character. He is left-footed, too, which offers us good options at the back. “He is still young but his progress in the game has been rapid. We feel confident his upward trajectory will continue here at City working with Pep and his staff.” Gvardiol is unlikely to make his City debut in Sunday’s Community Shield against Arsenal but could be in contention for their Premier League opener at Burnley on Friday. Read More Barcelona landed one Man City star for free - now Pep Guardiola won’t allow another Pep Guardiola keen to avoid ‘difficult’ transfer task after Man City lose ‘incredible players’ When is the Community Shield? How to watch Arsenal vs Man City online and on TV this weekend

Quarterback Justin Fields will likely miss the Chicago Bears' game against the Las Vegas Raiders because of a dislocated right thumb

A treatment for acute migraines has been approved for NHS use for the first time, with experts saying the move could be a “step-change” for thousands of people who suffer from the condition. The National Institute for Health and Care Excellence (Nice) said its final draft guidance on Rimegepant “addresses the high unmet need for treatment options for acute migraine”. Rimegepant, also known as Vydura and made by Pfizer, will be available to adults who have tried at least two triptans – medication usually given to tackle headaches or migraines – but found they did not work well enough. It can also be administered to those who are not able to take triptans or have an intolerance, or patients who have tried nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol. Helen Knight, director of medicines evaluation at Nice, said: “Migraine is a condition described in comments to Nice from carers and people with migraine as an invisible disability that affects all aspects of life including work, education, finances, mental health, social activities and family. “Today’s final draft guidance addresses the high unmet need for treatment options for acute migraine, once again demonstrating our ability to ensure clinically and cost-effective medicines are available to those who need them as quickly as possible.” Rimegepant is taken as a wafer, which dissolves under the tongue and works by stopping the release of a protein around the brain called calcitonin gene-related peptide. In July, the medicine was recommended as an option for preventing episodic migraines in adults who have at least four and fewer than 15 attacks per month if “at least” three other treatments have not worked. This is the first and only Nice-recommended medicine that can help alleviate the misery of acute migraines, and may be considered a step-change in treatment Helen Knight, Nice Under the latest guidance, it will also be used to relieve symptoms of a migraine, which can include pain, nausea and sensitivity to light, but also painless symptoms such as temporary visual disturbances known as “aura”, which Nice said “is not well managed with existing treatments”. The recommendation is expected to benefit about 13,000 people. Ms Knight added: “This is the first and only Nice-recommended medicine that can help alleviate the misery of acute migraines, and may be considered a step-change in treatment.” Migraine is an incredibly misunderstood condition that can have a significant impact on all areas of life, including ability to work, maintain relationships and mental health Robert Music, The Migraine Trust Robert Music, chief executive of The Migraine Trust, said the Nice guidance “provides people with migraine valuable options to help reduce the pain and length of a migraine attack”. “It brings new hope,” he added. “It will especially benefit those who have not found a treatment that works, those who get debilitating side effects – including medicine overuse headache – from them, and those with cardiovascular disease who cannot take existing treatments. “Migraine is an incredibly misunderstood condition that can have a significant impact on all areas of life, including ability to work, maintain relationships and mental health.” Read More NHS winter resilience fund announced by Government NHS reliance on paper notes ‘stopping trusts from realising full potential’ Recession fears as UK economy shrinks by more than expected in shock decline Charity boss speaks out over ‘traumatic’ encounter with royal aide Ukraine war’s heaviest fight rages in east - follow live

British companies reported an unexpected increase in output in November and evidence of stronger inflation, signs of strength

Paige Spiranac highlighted gender bias and hypocrisy in the golf industry, emphasizing the differences she experiences compared to her male peers

By David Shepardson WASHINGTON The U.S. House of Representatives voted 221 to 203 on Tuesday to overturn Environmental

As we enter Week 5 of the NBA MVP race, there's still a clear frontrunner in Denver Nuggets big man Nikola Jokic. But, he faces stiff competition.

The Biden administration will announce a redoubling of measures to strengthen supply chains on Monday, expanding an effort

The Texas Rangers will skip All-Star right-hander Nathan Eovaldi for one turn through the rotation as part of a plan to give all their starters some rest